SCHEMBL4723219

SCHEMBL4723219

COc1ccc(C(CNC=O)c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.49
CNR1 P21554 1/20 0.49
ACP3 P15309 1/20 0.49
KMT2A Q03164 8/20 0.46
MEN1 O00255 6/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CRHBP P24387 1/20 0.46
CYP2C19 P33261 1/20 0.46
CRHR2 Q13324 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549013 0.84 GRIN1 (0.50) KMT2AMEN1KDM4ECYP2D6ALDH1A1
SCHEMBL11280865 0.80 HPGD (0.45) KMT2AMEN1LMNAHTTKDM4E
SCHEMBL16301227 0.80 SLC6A2 (0.55) CNR2CNR1ACP3KMT2AMEN1
SCHEMBL7523694 0.79 MEN1 (0.51) KMT2AMEN1LMNAHTTCYP1A2
SCHEMBL3443780 0.79 AOC3 (0.63) TDP1KDM4EGAASMN1; SMN2CYP1A2
Anisaldehyde SCHEMBL9536129 0.79 KDM4E (0.54) ACP3KMT2AMEN1TDP1KDM4E
SCHEMBL6211895 0.79 ALDH1A1 (0.50) CNR2KMT2AMEN1HTTTDP1
SCHEMBL6698808 0.78 ACP3 (0.53) CNR2CNR1ACP3KMT2AMEN1
SCHEMBL4723215 0.77 CNR2 (0.49) CNR2CNR1ACP3KMT2AMEN1
SCHEMBL20041847 0.77 FFAR1 (0.45) KMT2AGAAALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689393-A4 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-12-17 EP disclosed
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors LEE DENNIS 2007-05-31 US disclosed
EP-1689393-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
WO-2005037198-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123561-A1 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors TNK2, CDC42BPB, CDC42BPA CNR2 4622/4885CNR1 4287/4885ACP3 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.